Eliminating international normalized ratio threshold for transfusion in pediatric patients with acute liver failure

Angela Lee1, Julianne Mendoza2, Aleah L Brubaker1

  • 1Division of Abdominal Transplantation, Department of Surgery, Stanford University, Stanford, California.

Clinical Transplantation
|February 11, 2020
PubMed

Insights

Using clinical judgment for transfusions in pediatric acute liver failure (ALF) patients is as safe as using an international normalized ratio (INR)-based threshold. This approach did not increase complications in ALF patients undergoing liver transplantation.

Area of Science:

  • Pediatric Hepatology
  • Transfusion Medicine
  • Liver Transplantation

Background:

  • Transfusion protocols for pediatric acute liver failure (ALF) are not well-established.
  • Evaluating transfusion strategies is crucial for optimizing outcomes in pediatric liver transplant recipients.

Purpose of the Study:

  • To assess the effectiveness and safety of an international normalized ratio (INR)-based transfusion threshold compared to clinical judgment in pediatric ALF patients.

Main Methods:

  • Retrospective review of 44 pediatric ALF patients from 2009-2018.
  • Comparison of two groups: INR threshold (INR > 3.0) vs. clinical judgment.
  • Analysis of preoperative INRs, transfusions, reoperations, renal/graft function, and survival.

Main Results:

  • The INR threshold group had lower preoperative INRs but received more fresh frozen plasma (FFP) and cryoprecipitate.
  • No significant differences were observed in pre-transplant bleeding, operative transfusions, or 1-year patient and graft survival between the groups.
  • Liver failure severity was comparable between the groups.

Conclusions:

  • An international normalized ratio (INR)-based transfusion threshold did not demonstrate superiority over clinical judgment in pediatric ALF patients.
  • Clinical judgment-based transfusion strategies are a safe alternative, avoiding increased perioperative complications.
Abstract

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
130
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
168
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
159